Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Molecular Therapeutics Overview Sparkline Graph

Graph co-Publications by faculty members in Molecular Therapeutics

Show all Molecular Therapeutics members

Publications (total of 2115)

no pagination
Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell cycle (Georgetown, Tex). 2018 Jan;:1-11.
Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell cycle (Georgetown, Tex). 2018 Jan;17(5):557-67.   PMCID: PMC5969548
Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical radiation oncology. 2018 Jan;8(1):40-7.
Jung K, Kang H, Mehra R. Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers of the head & neck. 2018 Jan;3:3.   PMCID: PMC6460806
Kline CL, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia (New York, NY). 2018 Jan;20(1):80-91.   PMCID: PMC5725157
Lin T, Hossain M, Fan J, Ma CC. When and how to treat an IMRT patient on a second accelerator without replanning?. Medical dosimetry : official journal of the American Association of Medical Dosimetrists. 2018 Jan;43(4):334-43.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123-36.   PMCID: Review
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner J, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology. 2018 Jan;14(2):123-36.
Reyngold M, Niland J, ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, Schrag D, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Advances in Radiation Oncology. 2018 Jan;3(1):34-41.   PMCID: PMC5856979
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Tamaki A, Miles BA, Lango M, Kowalski L, Zender CA. AHNS Series: Do you know your guidelines? Review of current knowledge on laryngeal cancer. Head & neck. 2018 Jan;40(1):170-81.
Vijayvergia N, Cohen SJ. Cytotoxic therapy in advanced pancreatic cancer: Where we are and where we are headed. In: Current and Emerging Therapies in Pancreatic Cancer. 2018. p. 205-17.
Lin T, Hossain M, Fan J, Ma CC. When and how to treat an IMRT patient on a second accelerator without replanning?. Medical dosimetry : official journal of the American Association of Medical Dosimetrists. 2017 Dec 26;.
Bryant KG, Chae YC, Martinez RL, Gordon JC, Elokely KM, Kossenkov AV, Grant S, Childers WE, Abou-Gharbia M, Altieri DC. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget. 2017 Dec 22;8(68):112184-98.   PMCID: PMC5762502
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SS, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Dec 20;35(36):4057-65.   PMCID: PMC5736236
Debenedetti PG, Klein ML. Chemical physics of water. Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13325-6.   PMCID: PMC5754819
Debenedetti PG, Klein ML. Chemical physics of water. Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13325-6.
Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell cycle arrest in colon cancer cells. Cancer Res. 2017 Dec 15;77(24):6902-13.
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33.   PMCID: PMC6075826
Wahab A, Kesari K, Chaudhary S, Khan M, Khan H, Smith S, Boumber Y. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?. Cancer Biol Ther. 2017 Dec 02;18(12):940-3.   PMCID: PMC5718810
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications by faculty members in Molecular Therapeutics


Show All Units
Last updated on Friday, January 03, 2020